Market Experts Bullish on Addus HomeCare’s Trajectory

Sentiment among financial analysts covering Addus HomeCare remains overwhelmingly favorable. The prevailing view points to significant upside potential for the home care provider's stock, supported by strong recent performance and robust growth forecasts.

A survey of thirteen research firms reveals that eleven currently advocate buying the shares. The collective average price target stands at $141.50, implying a potential appreciation of more than 17% from current trading levels. While analyst projections vary, reflecting a spectrum of assumptions, the overall confidence is clear. Targets range from a conservative $117.00 to a bullish $160.00.

Recent Revisions to Price Forecasts

Several institutions have recently reaffirmed or upgraded their assessments:
* On November 7, 2025, RBC Capital maintained its "Buy" recommendation while raising its price objective from $134.00 to $139.00.
* TD Cowen continued its "Strong Buy" stance on November 5, increasing its target from $139.00 to $140.00.

A more cautious perspective exists alongside this optimism. BMO Capital initiated coverage on November 13 with a "Hold" rating and a $120.00 price target. Meanwhile, Barclays sustains a "Sell" recommendation, though it lifted its target from $111.00 to $117.00 on November 4.

Strong Quarterly Results Underpin Confidence

The positive analyst outlook is grounded in solid financial fundamentals. Addus HomeCare's third-quarter 2025 results exceeded market expectations. Adjusted earnings per share (EPS) came in at $1.56, surpassing the forecast of $1.53.

Should investors sell immediately? Or is it worth buying Addus HomeCare?

Revenue demonstrated considerable year-over-year growth, climbing 25% to reach $362.3 million. Key profitability metrics also showed positive momentum, reinforcing the company's financial health:
* Adjusted EBITDA expanded by 31.6% to $45.1 million.
* Operating cash flow exceeded $50 million.
* The gross margin improved to 32.2%.

The Personal Care and Hospice service segments were primary contributors to these results. Management is monitoring the Home Health division, however, as potential cuts to Medicare reimbursements present a recognized risk factor.

Sustained Growth Projected

The financial roadmap for Addus HomeCare appears well-defined. For the full 2025 fiscal year, revenue is anticipated to grow 25.5% to approximately $1.45 billion. Adjusted EPS is projected to surge roughly 47.5% to $6.24.

Looking further ahead, analysts model continued expansion for 2026. Revenue is forecast to increase just over 7% to $1.55 billion, with earnings per share potentially reaching $6.91. These projections highlight the company's sustained growth narrative within the expanding market for home-based care services.